The North America Duchenne muscular dystrophy (DMD) treatment market reached US$2.06 billion in 2024 and is projected to grow at a 20.2% CAGR, hitting US$8.84 billion by 2033, driven by rising prevalence and breakthroughs in gene and exon-skipping therapies. https://www.datamintelligence.com/research-report/north-america-duchenne-muscular-dystrophy-treatment-market